Tumor Effect Articles & Analysis: Older
50 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development ...
” Jurgen Fütterer, professor of Image-Based Oncological Interventions at Radboudumc, said “Previous research shows that focal therapy is a safe option with good tumor control and few side effects. We now want to investigate this in the Netherlands as well and reduce the risk of bothersome side effects for future patients. ...
“Immunotherapies are a cornerstone in current treatment options for tumors, and we are excited to see these in vivo data show the ability of a single treatment of UNO when used in combination with anti-PD-1 have a positive impact on tumor regression rates and overall survival. ...
The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”). ...
About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s ...
About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s ...
More importantly, NIR quantum dots consist of stronger penetration capability in tumor-targeted imaging, which can effectively avoid tissue absorption and autofluorescence. ...
Meanwhile, soy peptides, consisting of immunomodulatory, antioxidant, and hypocholesterolemic effects, are reported to be beneficial to diabetes, obesity, serum lipids, etc. ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
As part of the RubrYc transaction, the Company now wholly-owns, with no further financial commitments, its lead immune-oncology asset, IBIO-101; an IL-2 sparing anti-CD25 antibody aimed at depleting immunosuppressive regulatory T cells without interfering with T effector cell anti-tumor effects. As iBio evaluates its recently increased options for the ...
INB-400 expands the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapies. ...
Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition. Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels. Microspheres embolization reduces or eliminates the ...
The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. ...
This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge diagnostic PARIS Test to first responders and other patients at Vincere Cancer Center. A patient’s tumor biopsy or surgical resection will be generated at Vincere and then sent to SEngine’s laboratory in Seattle, where up to 44 drugs from a library of over 240 options ...
The shares were offered by IN8bio pursuant to a registration statement on Form S-1 (File No. 333-266620) that was previously filed with, and subsequently declared effective on August 11, 2022, by the U.S. Securities and Exchange Commission (SEC). The offering was made only by means of a prospectus that formed a part of the effective registration statement. The ...
About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s ...
“These tumors are known to be hypoxic, which reduces the effectiveness of radio-, chemo-, and immunotherapeutic approaches and promotes tumor cell metastases. ...
ByCervoMed
This European patent expands our coverage to include NK cells, the other innate immune effectors that can respond to upregulated cellular stress to directly kill tumor cells,” said William Ho, CEO and co-founder of IN8bio. “Our unique DRI approach provides the ability to upregulate multiple NKG2D-ligands on the tumor cell surface, which allows for the ...
Judah Folkman, a pioneer in the area of anti-angiogenesis for solid tumors, at Harvard Medical School, whose research contributed to a number of approved products, most notably the development of Avastin®. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an ...